AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by CPE – Virucidal compounds
When evaluating the antiviral effect of a compound, assessing cellular toxicity in the target cell line is an essential prerequisite (see dedicated SOP). The highest dose allowing > 90 % cell viability is the first tested dose in antiviral assay. SARS-CoV-2, WNV and CHIKV infections on Vero E6 cell line causes a cytopathic effect (CPE) that can be used as a simple, low-cost first-line method for evaluating the antiviral efficacy of compounds.
Authors
- Anne Bull-Maurer
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-05-27
- DOI
- https://doi.org/10.5281/zenodo.20408028
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00